The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma - 18/11/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | We outline the rationale for the combination between lenvatinib and anti-PD-1 and clinical trials to support this "golden combination". |
• | We also discuss the commonly treatment-emergent adverse events (AEs) and solutions for advanced HCC. |
• | Finally, we focus on the novel approaches, future perspectives and potential challenges about the combination of TKIs and ICIs. |
• | Based on the approvement of the combination between atezolizumab and bevacizumab (A + T) for HCC, we compared the efficacy of “lenvatinib + pembrolizumab” and " atezolizumab + bevacizumab " in the phase I study. |
Abstract |
China has one of the highest incidence rates of hepatocellular carcinoma (HCC) in the world. As most patients are diagnosed with advanced or unretractable HCC, systematic therapy is still the main treatment method for HCC. Currently, tyrosine kinase inhibitors (TKIs) and Immune checkpoint inhibitors (ICIs) are both the chief systematic therapy. And some studies have shown that the combination of TKIs and ICIs is more effective than monotherapy. The purpose of this review is to outline the rationale for the combination between lenvatinib and anti-PD-1(programmed cell death 1) and clinical trials to support this "golden combination". We also discuss the commonly treatment-emergent adverse events (AEs) and solutions for the patients with HCC who received the combination between lenvatinib and anti-PD-1 antibodies. Finally, we focus on the novel approaches, future perspectives and potential challenges about the combination of TKIs and ICIs.
Le texte complet de cet article est disponible en PDF.Keywords : Lenvatinib, Immune checkpoint therapy, Pembrolizumab, Nivolumab, Hepatocellular carcinoma
Plan
Vol 132
Article 110797- décembre 2020 Retour au numéro
Article précédent
- The cells involved in the pathological process of diabetic retinopathy
- Songtao Yang, Jiaoyue Zhang, Lulu Chen
- Panax ginseng clinical trials: Current status and future perspectives
- Shasha Fan, Zepeng Zhang, Hang Su, Peng Xu, Hongyu Qi, Daqing Zhao, Xiangyan Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?